Login
Companies $SANA
$1.89 +$0.01 (0.53%) After hours
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

sana.com

What Do They Do?

Develops therapies made from engineered cells for people with diabetes, B cell cancers, and B cell-mediated autoimmune diseases.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ Turned profitable
vs −$42.2M in Q3 FY2025

A narrower pipeline The earlier report described a broad pipeline spanning oncology, diabetes, central nervous system and genetic disorders, including allogeneic CAR T programs. The latest report centers on diabetes and B cell diseases, and says development of some allogeneic CAR T programs is suspended.

Who Do They Compete With?

Competes with AbbVie, Allogene Therapeutics, Aspect Biosystems, AstraZeneca, Bristol-Myers Squibb, Cabaletta Bio, Caribou Biosciences, Century Therapeutics, CRISPR Therapeutics, Eli Lilly, Gilead Sciences, Johnson & Johnson, Kelonia Therapeutics, Kyverna Therapeutics, Legend Biotech, Novartis, Roche, Umoja Biopharma, and Vertex Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support